


Molecular characterization of CA125 in Benign and Malignant Ovarian Tumors



Immunoradiometric assay technique was used to measure the level of serum tumor markers CA125 and CEA in 30 healthy women, 24 patients with benign ovarian tumors and 34 patients with malignant ovarian tumors. Upon comparison of the results, the CA125 level was found above normal (35u.ml-1) in 80% of patients with ovarian cancer, while CEA level was elevated in 44% of patients with ovarian cancer (more than 3.0 u.ml-1). Among the pre-menopausal women, the values of CA125 and CEA in sera of patients with malignant ovarian tumors were found to be significantly higher (PModified immunoradiometric assay (IRMA) was used to characterize the binding of ¹²⁵I-antiCA125 antibody to CA125 in the supernatant fraction of ovarian tumor homogenates. Different factors affecting this binding were extensively studied such as pH, time, temperature, concentration of salts, concentration of antibodies and concentration of antigens CA125 of homogenate obtained from post-menopausal patients with malignant ovarian tumor was partially purified by gel filtration technique. Two forms of CA125 were found (BI and BII) with molecular weights 670 and 100 kDa respectively. The binding characteristics of the partial purified CA125 with ¹²⁵I-antiCA125 antibody were investigated. Kinetic parameters of the binding of ¹²⁵I-antiCA125 antibody with CA125 of homogenate obtained from pre-menopausal patients with benign and malignant tumors, post-menopausal patients with malignant tumors, and partially purified CA125, at different temperatures were determined. The results indicated that the binding reaction was time and temperature dependent process and it follows second order rate law in all studied groups. The thermodynamics of the binding of ¹²⁵I-antiCA125 antibody with CA125 of homogenate obtained from pre-menopausal

patients with benign and malignant tumors, post-menopausal patients with malignant tumors, and the partially purified CA125, at different temperatures were determined. All studied groups showed exothermic and spontaneous reactions and the participation of enthalpy was low. Thermodynamic parameters of transition state (ΔH^* , ΔG^* , ΔS^*) and activation energy (E_a) were also determined. Spectroscopic studies, in the U.V region, were carried out on the complex (125I-antiCA125 antibody/CA125) formed of the partially purified CA125, from post-menopausal patients with malignant ovarian tumors, to its specific antibody. Different factors affecting the absorption band such as pH, polarity and denaturation agents were extensively studied. The heat stability and spectrophotometric pH titration of the complex were also included in this work.

[\[PDF\] Dont Stop Loving Me: A Reassuring Guide for Mothers of Adolescent Daughters](#)

[\[PDF\] Seismological Research Letters, Seismological Society of America, 2005, Seismological Research Letters, 76 \(1\)](#)

:-

[\[PDF\] Progress in Self Psychology, V. 1](#)

[\[PDF\] The pathology of mind \(1879\)\[ILLUSTRATED EDITION\]](#)

[\[PDF\] Petrology for Students](#)

[\[PDF\] Semi-quantitative Approaches for Landslide Assessment and Prediction \(Springer Natural Hazards\)](#)

[\[PDF\] The Assassination of President Kennedy \(Dates with History\)](#)

MUC16 (CA125): tumor biomarker to cancer therapy, a work in CA125 identity in characterization studies will help establish a refined model The discovery of CA125 represented a milestone for ovarian cancer detection. when distinguishing benign from malignant ovarian disease [4]. **Molecular characterization of ca125 in benign and malignant** Keywords: ovarian cancer, molecular imaging, PET, SPECT, ultrasound, MRI particularly in distinguishing between benign and malignant ovarian lesions that are PET/CT in the context of tumor characterization and staging (8). . of an ^{89}Zr -labeled radioimmunoconjugate based on the CA125-targeting One tumor biomarker, the cancer antigen 125 (CA125) is commonly used preoperatively Many benign ovarian conditions and nongynecologic conditions are also . Molecular approaches to the discovery of new ovarian cancer biomarkers .. that characterize long-term survival in advanced stage serous ovarian cancers. **Molecular Characterization of Ca125 in Benign and Malignant** Compre o livro Molecular Characterization of Ca125 in Benign and Malignant Ovarian Tumors na : confira as ofertas para livros em ingles e **and Decreased IGFBP-3 in Epithelial Ovarian Cancer** Ovarian cancer is the second most common female gynaecological cancer in the The CA 125 molecule is a 200-kDa glycoprotein and was initially The patient characteristics and radiological information provides crucial **Serum CA 125 and ovarian cancer - CLI** Cancer antigen 125 (CA-125) is a high molecular weight glycoprotein that is Because most ovarian masses detected by ultrasound screening are benign, it is scored four different morphologic characteristics of ovarian cyst architecture, **Serum CA19-9 as a Predictor of Malignancy in Primary Ovarian** Molecular characterization of CA125 in Benign and Malignant Ovarian Tumors (English Edition) eBook: Sami AL-Mudhaffar: : Kindle-Shop. **Molecular Imaging of Ovarian Cancer - NCBI - NIH** Molecular characterization of CA125 in Benign and Malignant Ovarian Tumors: CA125 in Tumors: Prof Sami A. AL-Mudhaffar Dr.: 9781523373253: Books **Borderline tumours of the**

ovary, current controversies regarding It is possible that because of the molecular heterogeneity of ovarian cancer a number of common benign conditions can cause elevation of CA125 levels, **CA125 in Ovarian Cancer - NCBI - NIH Molecular characterization of CA125 in Benign and Malignant** Prof Sami A. - Molecular characterization of CA125 in Benign and Malignant Ovarian Tumors: CA125 in jetzt kaufen. ISBN: 9781523373253, Fremdsprachige **Pelvic mass associated with raised CA 125 for benign condition: a** Molecular characterization of ca125 in benign and malignant ovarian tumors ca125 in tumors pdf. **Deciphering the Molecular Nature of Ovarian Cancer - MDPI Molecular characterization of CA125 in Benign and Malignant** Buy Molecular characterization of CA125 in Benign and Malignant Ovarian Tumors: CA125 in Tumors on ? FREE SHIPPING on qualified orders. **Tietz Textbook of Clinical Chemistry and Molecular Diagnostics - - Google Books Result** determinant found on a high molecular weight Workshop studying the characteristics and epitope CA 125 in benign diseases and non-ovarian cancer. **Molecular characterization of CA125 in Benign and Malignant** Molecular characterization of CA125 in Benign and Malignant Ovarian Tumors eBook: Sami AL-Mudhaffar: : Kindle Store. **Ovarian Cancer Screening and Early Detection in the General** The molecular changes in borderline ovarian tumors indicate linkage of . of first benign, then borderline and finally malignant characteristics could .. Indeed, there is a high risk of false-positive CA125 results due to a variety **Early detection of ovarian cancer - NCBI - NIH** CA 125 is not useful in screening for ovarian cancer in asymptomatic for malignant ovarian masses is far more extensive than that for benign masses. and only 50% of clear cell and 0% of mucinous tumors.⁷⁴ The protein is characterized **Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors** Keywords: CA 125, biomarker, detection, disease monitoring, ovarian cancer, pregnancy, CA125 levels have also been found elevated in benign conditions [22, 23] such as Denatured purified subspecies of the CA125 molecule appear to . The lead time gained by screening is a function of the characteristics of the **Molecular characterization of CA125 in Benign and Malignant** Molecular characterization of CA125 in Benign and Malignant Ovarian Tumors: CA125 in Tumors by Prof Sami A. AL-Mudhaffar Dr. (2016-01-13) Pasta blanda **Ovarian Cancer Biomarkers: Current Options and Future Promise** Buy Molecular characterization of CA125 in Benign and Malignant Ovarian Tumors: CA125 in Tumors by Prof Sami A. AL-Mudhaffar Dr. (2016-01-13) on **Molecular characterization of CA125 in Benign and Malignant** In addition, differentiation of malignant tumors from benign tumors will be more challenging if The serum level of CA 19-9 and CA 125 were determined by Clinical characteristics in association with serum CA19-9 elevation in .. of candidate molecular markers for ovarian cancer diagnosis and therapy. **MUC16 (CA125): tumor biomarker to cancer - Molecular Cancer** Epithelial tumours of the ovary can be either benign (cystadenomas) or of these implants have microscopic characteristics of stromal invasion of epithelial ovarian tumours, based on their molecular differences and The tumour marker CA-125 may be high in more than half of the patients with BOT [8]. **Molecular characterization of ca125 in benign and malignant** Ovarian cancer CA125 MUC16 Cancer biomarker Metastasis detection of ovarian cancer, (2) to distinguish between benign and malignant disease in . A more definitive study on the molecular characterization of CA125 by **Mucins in ovarian cancer diagnosis and therapy - NCBI - NIH** system of low-molecular weight peptides that promote cell proliferation and were characterized in detail in terms of levels of tumor markers (serum. CA 125 and with benign ovarian tumors and normal CA 125 values (35 U/mL) mean: 16